Details

Autor(en) / Beteiligte

• FRIEDMAN, Henry S
• KEIR, Stephen T
• HOUGHTON, Peter J
• LAWLESS, Amy A
• BIGNER, Darell D
• WATERS, Stephen J

Titel

Activity of irofulven (6-hydroxymethylacylfulvene) in the treatment of glioblastoma multiforme-derived xenografts in athymic mice

Ist Teil von

• Cancer chemotherapy and pharmacology, 2001-11, Vol.48 (5), p.413-416

Ort / Verlag

Berlin: Springer

Erscheinungsjahr

2001

Link zum Volltext

Quelle

SpringerLINK Contemporary (Konsortium Baden-Württemberg)

Beschreibungen/Notizen

• This study was conducted to define the activity of irofulven in the treatment of a series of xenografts derived from human glioblastoma multiforme growing subcutaneously and intracranially in athymic nude mice. Athymic mice bearing subcutaneous or intracranial tumors were treated with irofulven at a 10% lethal dose with responses compared to tumor-bearing mice treated with drug vehicle. Irofulven was active against all tumor lines tested with growth delays ranging from 5.6 to 81.6 days (all values statistically significant, P < or = 0.001). Irofulven also produced a statistically significant (P < or = 0.001) increase in the median survival of mice bearing D-456 intracranial xenografts with a 162% increase in median survival. Irofulven is active in a spectrum of human glioblastoma multiforme-derived xenografts and evaluation in patients with this neoplasm is warranted.